Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12345678910111213...1516»
  • ||||||||||  CATALYZING ACCESS TO RESEARCH AND EQUITY REPRESENTATION: CLINICAL TRIAL "DIVERSITY SCORECARDS" FOR CARDIOVASCULAR DRUGS (Room 357; [In-Person]; [Virtual]; [Virtual On Demand]; [ACC Anywhere]) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_8601;    
    Recent guidelines have called for more standardized reporting of diversity in clinical trials, but do not specify translation into actionable recommendations. Critique of this and other diversity scorecards is warranted, particularly around standardization of race and ethnicity, sex and gender minorities, as well as disabilities.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    WHO? CHARACTERIZING VERICIGUAT USE IN A REAL-WORLD HFREF PATIENT POPULATION (Heart Failure and Cardiomyopathies Moderated Poster Theater 11_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1106;    
    Only a third reached target dose of vericiguat by the end of the study period. Additional research to better understand characteristics of patients with WHF including concomitant treatment patterns and real-world effectiveness of vericiguat in light of current guidelines is needed.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Trial initiation date:  The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation (clinicaltrials.gov) -  Dec 30, 2022   
    P4,  N=24, Not yet recruiting, 
    Additional research to better understand characteristics of patients with WHF including concomitant treatment patterns and real-world effectiveness of vericiguat in light of current guidelines is needed. Initiation date: Dec 2022 --> May 2023
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Journal:  Aiming at harmony. Comparing and contrasting International HFrEF Guidelines. (Pubmed Central) -  Dec 23, 2022   
    Specific treatments, mostly new, for cardiovascular and non-cardiovascular comorbidities are also given. The aim of this article is to compare the two recent guidelines issued by the ESC and ACC/AHA/HFSA and show the few differences and the many consistent recommendations, now more numerous given the evidence available for many new treatments.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat (Verquvo) for the Treatment of Heart Failure. (Pubmed Central) -  Nov 22, 2022   
    The aim of this article is to compare the two recent guidelines issued by the ESC and ACC/AHA/HFSA and show the few differences and the many consistent recommendations, now more numerous given the evidence available for many new treatments. No abstract available
  • ||||||||||  Journal:  Current updates in the pharmacotherapy of heart failure with a preserved ejection fraction. (Pubmed Central) -  Nov 5, 2022   
    EMPEROR-PRESERVED (Empagliflozin) and PRESERVED-HF (Dapagliflozin) results in the management of HFpEF look promising irrespective of diabetes status. Sacubitrilvalsartan and Empagliflozon are the only medications approved for its management as per the PARAGON-HF and EMPEROR-PRESERVED studies, respectively.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Journal:  Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. (Pubmed Central) -  Oct 28, 2022   
    Consequently, blood pressure is reduced by beta blockers, renin-angiotensin-aldosterone system inhibitors, sacubitril/valsartan, and, minimally, by SGLT2 inhibitors and vericiguat; heart rate decreases with beta blockers and ivabradine; and renal function is impaired and potassium are levels increased with renin-angiotensin-aldosterone system inhibitors and sacubitril/valsartan. Practical recommendations on how to individualize HF therapy according to patient profile are provided.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction Across the Risk Spectrum. (Pubmed Central) -  Oct 18, 2022   
    Vericiguat, an sGC stimulator, was shown to improve outcomes in patients with HFrEF in the VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial...Third, the effect of vericiguat on cardiovascular mortality remains uncertain and a trial with a longer follow-up in a lower-risk population may allow better assessment of its effect on cardiovascular mortality. Therefore, there is a pertinent need to investigate the effects of vericiguat in optimally-treated, low-risk HFrEF patients (i.e., those without recent worsening heart failure).
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, Merck (MSD)
    Review, Journal:  Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. (Pubmed Central) -  Oct 12, 2022   
    sGC stimulators, in turn, are effective both in PAH and in HF due to their balanced pulmonary and systemic vasodilation, and as such they are preferable to PDE-5i if the use of a pulmonary vasodilator is needed in HF patients, including those listed for LVAD implantation. Regarding the effectiveness of PDE-5i and sGC stimulators when initiated post LVAD implant, these two groups of compounds should be tested in a randomized control trial.
  • ||||||||||  Review, Journal:  Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. (Pubmed Central) -  Oct 4, 2022   
    Recent large-scale clinical trials have demonstrated the efficacy of newer pharmacological agents including angiotensin II receptor/neprilysin inhibitor (ARNI), sacubitril/valsartan, type 2 sodium-glucose cotransporter (SGLT2) inhibitors, dapagliflozin, empagliflozin and sotagliflozin, and soluble guanylyl cyclase (sGC) stimulator, vericiguat, and cardiac myosin activator, omecamtiv mecarbil. This review focuses the recent advances in the pharmacological agents for treatment of chronic heart failure, including their mechanisms of action, the evidence based on the clinical trials, and the guideline recommendations for their use.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    New and Emerging Therapeutic Options for WHF in HFrEF: Vericiguat and Omecamtiv Mecarbil (Gaylord National Convention Center Ballroom: National Harbor 2/3 201 Waterfront Street National Harbor, Maryland) -  Sep 24, 2022 - Abstract #HFSA2022HFSA_900;    
    This review focuses the recent advances in the pharmacological agents for treatment of chronic heart failure, including their mechanisms of action, the evidence based on the clinical trials, and the guideline recommendations for their use. Supported by an unrestricted educational grant from Cytokinetics Incorporated.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Kerendia (finerenone) / Bayer
    Horizon Therapies for HF: How will we fit them in? (National Harbor 2/3) -  Sep 24, 2022 - Abstract #HFSA2022HFSA_586;    
    Supported by an unrestricted educational grant from Cytokinetics Incorporated. Integration of second-line therapies (vericiguat, digoxin, potassium binders) and potential role of horizon treatments including omecamtiv mecarbil/finerenone.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    New Drugs - Vericiguat (Potomac C) -  Sep 24, 2022 - Abstract #HFSA2022HFSA_569;    
  • ||||||||||  Review, Journal, HEOR:  Cost effectiveness analyses of pharmacological treatments in heart failure. (Pubmed Central) -  Sep 23, 2022   
    In order for more precise analysis on cost effectiveness analysis, it is necessary to take into account the income level of various countries as it is certainly easier to allocate more financial resources for the intervention, with greater effectiveness, in high- and middle-income countries than in low-income countries. This review aims to evaluate evidence and cost effectiveness studies in more recent HF drugs i.e., SGLT2i, ARNi, ivabradine, vericiguat and omecamtiv, and gaps in current literature on pharmacoeconomic studies in HF.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Biomarker, Clinical, Review, Journal:  A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC. (Pubmed Central) -  Sep 11, 2022   
    Future studies should seek to adopt unbiased approaches for discovery of true companion diagnostics; with -omics-based tools, biomarkers might be more precisely selected for use in clinical trials to identify responses that closely reflect the biological effects of the drug under investigation. Finally, biomarkers associated with cardiac damage and remodelling, such as cardiac troponin, could be employed as safety endpoints provided that standardization between different assays is achieved.
  • ||||||||||  Cost-Effectiveness of Heart Failure Treatments– A Targeted Literature Review (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_580;    
    Results of our review can be useful for physicians and other decision-makers to prescribe appropriate treatments for CHF. Evidence on the cost-effectiveness of medical devices is limited, suggesting an unmet need for an appropriate and economic treatment option in patients uncontrolled on pharmacological therapy.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    PK/PD data, Preclinical, Journal:  Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats. (Pubmed Central) -  Aug 31, 2022   
    Clearance routes in both species were unchanged excretion and metabolism via glucuronidation and oxidative reactions. After intravenous administration to bile duct cannulated rats, a relevant proportion of the dose (30%) underwent direct excretion into the gastrointestinal tract as unchanged vericiguat.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Worsening heart failure in Colombia: Analysis from RECOLFACA registry. (Pubmed Central) -  Aug 31, 2022   
    Patients enrolled in the RECOLFACA that met the VICTORIA definition had more similar characteristics and outcomes compared to the VICTORIA population. There is an opportunity to improve this unmet need with the use of vericiguat.